​
​

Nektar Therapeutics Ownership | Who Owns Nektar Therapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

Nektar Therapeutics Ownership Summary

Nektar Therapeutics is owned by 69.51% institutional investors, 1.06% insiders, and 29.43% retail investors. Deep track capital, lp is the largest institutional shareholder, holding 9.18% of NKTR shares. Eventide Healthcare & Life Sciences I is the top mutual fund, with 4.09% of its assets in Nektar Therapeutics shares.

NKTR Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockNektar Therapeutics69.51%1.06%29.43%
SectorHealthcare Stocks 47.25%8.01%44.75%
IndustryBiotech Stocks 45.35%7.81%46.83%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Eventide Healthcare & Life Sciences I7.53M4.09%7.53M
Vanguard Total Stock Mkt Idx Inv5.72M3.10%-
iShares Russell 2000 ETF4.80M2.61%-10.78K
PRIMECAP Odyssey Aggressive Growth3.69M2.01%-
Vanguard Institutional Extnd Mkt Idx Tr2.92M1.59%-
Fidelity Small Cap Index1.83M1.00%-41.73K
iShares Russell 2000 Value ETF1.76M0.96%-
PRIMECAP Odyssey Growth1.61M0.87%-93.30K
Vanguard Strategic Equity Inv1.52M0.82%-
BlackRock Advantage Small Cap Core Instl1.01M0.55%42.92K

Recent Insider Transactions

DateNameRoleActivityValue
Aug 19, 2024Zalevsky Jonathan Chief R&D OfficerSell$8.79K
Aug 19, 2024Wilson Mark Andrew Chief Legal OfficerSell$7.23K
Aug 19, 2024ROBIN HOWARD W President & CEOSell$19.05K
Jun 14, 2024CHESS ROBERT-Sell$23.40K
May 17, 2024ROBIN HOWARD W President & CEOSell$29.14K

Insider Transactions Trends

DateBuySell
2024 Q3-3
2024 Q2-5
2024 Q1-3
2023 Q4-3
2023 Q3-5

NKTR Ownership FAQ

Who Owns Nektar Therapeutics?

Nektar Therapeutics shareholders are primarily institutional investors at 69.51%, followed by 1.06% insiders and 29.43% retail investors. The average institutional ownership in Nektar Therapeutics's industry, Biotech Stocks , is 45.35%, which Nektar Therapeutics exceeds.

Who owns the most shares of Nektar Therapeutics?

Nektar Therapeutics’s largest shareholders are Deep track capital, lp (17.88M shares, 9.18%), Blackrock (15.16M shares, 7.78%), and Vanguard group (12.97M shares, 6.66%). Together, they hold 23.62% of Nektar Therapeutics’s total shares outstanding.

Does Blackrock own Nektar Therapeutics?

Yes, BlackRock owns 7.78% of Nektar Therapeutics, totaling 15.16M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 18.79M$. In the last quarter, BlackRock increased its holdings by 9.28M shares, a 157.82% change.

Who is Nektar Therapeutics’s biggest shareholder by percentage of total assets invested?

Cm management is Nektar Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.85% of its assets in 750K Nektar Therapeutics shares, valued at 930K$.

Who is the top mutual fund holder of Nektar Therapeutics shares?

Eventide Healthcare & Life Sciences I is the top mutual fund holder of Nektar Therapeutics shares, with 4.09% of its total shares outstanding invested in 7.53M Nektar Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools